Risk of aplastic anemia in patients using antiepileptic drugs

Epilepsia

Volumn 47, Issue 7, 2006, Pages 1232-1236

  Handoko, Kim B ^a,b   Souverein, Patrick C ^a   Van Staa, Tjeerd P ^a,c   Meyboom, Ronald H B ^a,d   Leufkens, Hubert G M ^a   Egberts, Toine C G ^a   Van Den Bemt, Patricia M L A ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Ziekenhuisapotheek Noordoost Brabant   (Netherlands)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

Antiepileptic drugs; Aplastic anemia; Case control study; Drug induced; GPRD

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, APLASTIC; ANTICONVULSANTS; CARBAMAZEPINE; CASE-CONTROL STUDIES; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FAMILY PRACTICE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; VALPROIC ACID;

EID: 33746158512     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2006.00596.x     Document Type: Article

References (15)

1. Tichelli A, Gratwohl A, Wursch A, et al. Late haematological complications in severe aplastic anaemia. Br J Haematol 1988; 69:413-8.
2. Man Fung F, Thornton A, Mybeck K, et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Info J 2001; 35:293-317.
3. Young NS. Acquired aplastic anemia. Ann Intern Med 2002; 136:534-46.
4. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22:62-5.
5. Blain H, Hamdan KA, Blain A, et al. Aplastic anemia induced by phenytoin: a geriatric case with severe folic acid deficiency. J Am Geriatr Soc 2002; 50:396-7.
6. Franceschi M, Ciboddo G, Truci G, et al. Fatal aplastic anemia in a patient treated with carbamazepine. Epilepsia 1988; 29:582-3.
7. Kaufman DW, Kelly JP, Anderson T, et al. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997; 38:1265-9.
8. Kaufman DW KJ, Levy M, Shapiro S. The drug etiology of agranulocytosis and aplastic anemia. New York: Oxford University Press, 1991.
9. Blackburn SC, Oliart AD, Garcia Rodriguez LA, et al. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 1998; 18:1277-83.
10. van Staa TP, Boulton F, Cooper C, et al. Neutropenia and agranulocytosis in England and Wales: incidence and risk factors. Am J Hematol 2003; 72:248-54.
11. Inman WH. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Br Med J 1977; 1:1504-5.
12. Linet MS, Markowitz JA, Sensenbrenner LL, et al. A case-control study of aplastic anemia. Leuk Res 1989; 13:3-11.
13. Marsh JC, Ball SE, Darbyshire P, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2003; 123:782-801.
14. WHO. International monitoring of adverse reactions to drugs: adverse reaction terminology. Uppsala: WHO Collaborating Centre for International Drug Monitoring, Sept 2005.
15. Palace J, Lang B. Epilepsy: an autoimmune disease? J Neurol Neurosurg Psychiatry 2000; 69:711-4.